COVID-19 Strengthens Ties Between UK MHRA & NICE On Access To Innovation
New partnerships forged between the UK medicines regulator and health technology assessment bodies during COVID-19 have resulted in an improved understanding of the benefits new drugs can bring to the NHS and how to manage their rapid introduction.
You may also be interested in...
The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.
The UK regulator, the MHRA, has published guidance on its new integrated pathway for innovative drug approvals, which it says is intended to bring together partners including health technology assessment agencies, health care bodies and patient organizations to offer “sustained collaboration” with drug developers.
A technical workshop is planned for later this year to identify common “use cases” for real-world evidence that are important to the European Medicines Agency, health technology assessment bodies and payers.